TG Therapeutics Investigational Trial Site

Atlanta, Georgia 30327

1 studies enrolling now · 4 studies all time

What they study most

Chronic Lymphocytic Leukemia, Multiple Sclerosis, Non Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Relapsing Multiple Sclerosis, Small Lymphocytic Lymphoma

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) — Stopped early
• Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials — Stopped early
• Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies — Completed